These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24088798)

  • 1. Sulfonylureas and meglitinides: historical and contemporary issues.
    Lamos EL; Stein SA; Davis SN
    Panminerva Med; 2013 Sep; 55(3):239-51. PubMed ID: 24088798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].
    Basit A; Riaz M; Fawwad A
    Vasc Health Risk Manag; 2012; 8():463-72. PubMed ID: 23028231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    Viardot A
    Ther Umsch; 2017; 74(8):423-431. PubMed ID: 29461148
    [No Abstract]   [Full Text] [Related]  

  • 4. The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
    Del Prato S; Pulizzi N
    Metabolism; 2006 May; 55(5 Suppl 1):S20-7. PubMed ID: 16631807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are sulfonylureas passé?
    Green JB; Feinglos MN
    Curr Diab Rep; 2006 Nov; 6(5):373-7. PubMed ID: 17076998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?
    Cordiner RLM; Pearson ER
    Diabetes Obes Metab; 2019 Apr; 21(4):761-771. PubMed ID: 30471177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 8. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms and Characteristics of Sulfonylureas and Glinides.
    Lv W; Wang X; Xu Q; Lu W
    Curr Top Med Chem; 2020; 20(1):37-56. PubMed ID: 31884929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hardly any hypoglycemias, constant weight--and still cost effective].
    MMW Fortschr Med; 2005 Nov; 147(47):72-3. PubMed ID: 16370200
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical efficacy of glimepiride].
    Kaneko T; Sakamoto N
    Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
    [No Abstract]   [Full Text] [Related]  

  • 12. Progressing From Metformin to Sulfonylureas or Meglitinides.
    Grant JS; Graven LJ
    Workplace Health Saf; 2016 Sep; 64(9):433-9. PubMed ID: 27621259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
    Massi-Benedetti M; Herz M; Pfeiffer C
    Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroglycopenic Seizures: Sulfonylureas, Sulfamethoxazole, or Both?
    Khan U; Seetharaman S; Merchant R
    Am J Med; 2017 Jan; 130(1):e29-e30. PubMed ID: 27593606
    [No Abstract]   [Full Text] [Related]  

  • 15. [Type 2 diabetes: hypoglycemia risk, weight gain... Will there soon be a new alternative to insulin?].
    MMW Fortschr Med; 2006 Sep; 148(37):54. PubMed ID: 17036907
    [No Abstract]   [Full Text] [Related]  

  • 16. Is it time to ban sulfonylureas?
    Ceriello A
    J Diabetes; 2020 Nov; 12(11):848-850. PubMed ID: 32767650
    [No Abstract]   [Full Text] [Related]  

  • 17. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes.
    Tuccori M; Wu JW; Yin H; Majdan A; Azoulay L
    Diabetes Care; 2015 Nov; 38(11):2083-9. PubMed ID: 26341130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 Diabetes: Progress Made but Still a Long Road to Travel to Reduce Disease Burden.
    Terra SG; Vincent J
    Clin Pharmacol Ther; 2015 Aug; 98(2):108-11. PubMed ID: 26013760
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of sulphonylureas in the management of type 2 diabetes mellitus.
    Rendell M
    Drugs; 2004; 64(12):1339-58. PubMed ID: 15200348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.